Merck KgaA Says Primary Endpoints Met In Two Phase II Trials For Tepotinib

German drug major Merck KgaA (MKGAY.PK) has announced positive results from two Phase II clinical trials of its investigational, targeted oncology molecule tepotinib in MET-positive, advanced hepatocellular carcinoma or HCC with Child-Pugh Class A liver function. The company noted that both studies met their primary endpoint.

from RTT - Biotech https://ift.tt/2LHSupA
via IFTTT